VTRS

Viatris Inc
$18.70+$0.03+0.16%Price as of Nov 3, 2026, 9:29 AM ET

Key stats

Market cap
21.5B
Open
—
Day range
—
52-week range
$9.92 – $19.51
Volume
42.5K
Avg volume
8.58M

Earnings

Q3 FY26Upcoming
Expected$0.65
Q2 FY26
Actual$-0.10
Q1 FY26
Actual$0.15
Q4 FY25
Actual$-0.29

Next earnings call Nov 5, 2026

About

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

Employees
30,000
Headquarters
Canonsburg, PA